As of Thursday, August 9, 2018, 71 of 76 participants enrolled and received study drug in the first-ever clinical trial of smoked marijuana (cannabis) for treatment of symptoms of posttraumatic stress disorder (PTSD) in U.S. veterans. Taking place at the Scottsdale Research Institute (SRI) in Phoenix, Arizona, this clinical trial will evaluate the safety and efficacy of four different potencies of marijuana for symptoms of PTSD in 76 U.S. veterans. Gabrielle Fortier, M.P.H., Clinical Research Associate of the MAPS Public Benefit Corporation (MPBC), will monitor the site September 4 – 7, 2018. Our recruitment website can be visited here. Learn more…